# Salt of S adenosyl L methionine, composition contaning such salt, preferably for pharmaceutical use, and process for preparing them.

## Abstract
The object of the invention is a salt of S adenosyl L methionine, and compositions containing it, preferably for human pharmaceutical and veterinary use, such salt being characterized in that it is a salt of an organic resin consisting of a polymer or copolymer with free or salified acidic functional groups.

## Claims
Clais 1. Salt of S adenosyl methionine, preferably for human and veterinary pharmaceutical use, characterized in that it is the salt of an organic resin consisting of a polymer or of a copolymer with free or salified acidic functional groups. 2. Salt as claimed in claim 1, characterized in that said resin is either 8 polymer or a copolymer of the polystyrenesulphonic type. 3. Salt as claimed in claim 1, characterized in that said resin is selected among the following products ion exchange resins of the type of crosslinked styrenedivinylbenzene with sulphonic functional groups lignin sulphonic copolymers and polymers polymethacrylic acids, either crosslinked or not polyacrylic acids, either crosslinked or not polysulphonic acids and correspond ing carboxyl salts, phosphonic salts, iminodiacetic salts, alkylphosphonic salts, alkylsulphonic salts, elk ylarylsulphonic salts, alkylarylphosphonic salts, either crosslinked or not membranes and filaments onto which acidic groups have been grafted halogenated and partly halogenated polymers and copolymers containing acidic functional groups. 4. Composition, preferably for human pharmaceutical use in the therapy of the arthrosis, periarthritis, and at cerebral level of the depression syndromes or for vet erinary use, characterized in that it contains a salt as claimed in one or more of preceding claims. 5. Process for the preparation of a salt according to one or more of the preceding claims, characterized in that a solution of active methionine is reacted with an organic resin consisting of a polymer or of a copolymer ith acidic functional groups. 6. Process as claimed in claim 5, characterized in that said resin is reacted with the active methionine contained in a cell culture broth. 7. Salt, composition and process as hereinabove dis closed, in particular in the Examples. CLAIMS FOR AUSTRIA CLAIMS 1. Process for the preparation of a salt of S adenosyl L methionine characterized in that a solution of active methionine is reacted with an organic resin consisting of a polymer or of a copolymer with free or salified acidic functional groups. 2. Process as claimed in Claim 1, characterized in that said resin is reacted with the active methionine contained in a cell culture broth. 3. Process as claimed in Claim 1, characterized in that said resin is either a polymer or a copolymer of the polystyrenesulphonic type. 4. Process as claimed in Claim 1, characterized in that said resin is selected among the following products ion exchange resins of the type of crosslinked styrenedivinylbenzene with sulphonic functional groups ligninsulphonic copolymers and polymers polymethacrylic acids, either crosslinked or not polyacrylic acids, either crosslinked or not polysulphonic acids and corresponding carboxyl salts, phosphonic salts, iminodiacetic salts, alkylphosphonic salts, alkylsulphonic salts, alkylarylsulphonic salts, alkylarylphosphonic salts, either crosslinked or not membranes and filaments onto which acidic groups have been grafted halogenated and partly halogenated polymers and copolymers containing acidic functional groups.

## Description
S Adenosyl I methionine Active Methionine, indicat ed by the abbreviation SAM is one of the most important sulphur containing compounds from the biological viewpoint, in that it takes part to many enzymatic transmethylation reaction, as donor of methyl groups. From here its therapeutical indications derive in the treatment of arthroses, periarthritis and at cerebral level in depression syndromes. As the transmethylation reactions are of fundamental importance in the physiology of all living beings, active methionine is of extreme interest from the physiological and therapeutical veiw points. The more known methods for preparing such compound are of three types the enzymatic method see Cantoni, J. Bioc.Chem., 189 203 1951 ibid 189 745 1951 ibid 204 407 1953 Cantoni, J. Am. Them. Soc. 74.2942 1952 Japan. Patent 80 96,099 July 21st 1980 the chetnical method see Baddiley and Jamieson, J. Chem. Soc. 1955 p. 1085 Clifford H. Shunt et al., U.S. Patent 2 969353, Jan. 24th 1961 the biological method see Aminoacid, 4 95 98 1961 Japan J.B.C., 229 1037 1957 J. Biol. Chem, Tsuchida et al. U.S. Pat. 3,962,034 8th Jun 1976 . In the problem of formulating active methionine in the form of compositions suitable for pharmaceutical use various troubles have been met, mainly connected with the difficulty of obtaining compositions stable for long time periods and therefore suitable to any types and ways of administration. Up to date, no pharmaceutical forms sexist of this drug, suitable to be administered by the oral way on ly some SAM salts are known, with ions such as chloride, sulphate and p toluenesulphonate ions, some of which can be administered by the parenteral way, they being however so not very stable and so hygroscopic, that they necessarily require complex processes to the pur pose of being formulated, such as e.g., freeze drying processes. Purpose of the present invention is to prepare active methionine in the form of a stable non hygroscopic salt, suitable to be administered by any ways, and to be prepared without any particular problems in the form of the most commonly used pharmaceutical copositions. According to the purposes of the invention, such aSAM salt is gastroresistant insoluble in water, yet capable of forming SAM solutions, when being sdequate ly treated capable of releasing SAM in situ at the in testinal level capable of being prepared in the form of compositions with controlled release characteristics. According to a further purpose of the invention, such pharmaceutical composition is produced on industrial scale, in a simple and substantially cheap way. Another purpose of the invention is to be able to extract SAM from liquids containing it, by means of a low cost process, and obtaining high quality compositions. These and other purposes which will be described in the following disclosure, are achieved by the present invention by means of a salt of S adenosyl It methionine, and compositions containing it, preferably for pharmaceutical use, characterized in that it is a salt of an organic resin consisting of a polymer or of a copolymer with acidic functional groups. According to the invention, the resin hich is used to form the salt of SAM is a polymer or a copolymer with acidic functional characteristics, whose acidic functions can be partly or totally salified. Such resin is preferably, but not limitedly, cross linked. The acidic functions can be e.g. sulphonic, phos phonic, carboxyl, iminodiacetic, aminoacidic, and so on, groups. Non imitative examples of resins within the purpose of the present invention are polystyrenesulphonic copolymer crosslinked ion exchange resins of the styrene divinyl benzene type, with sulphonic functional groups ligninsulphonic copolymers and or polymers crosslinked or not crosslinked polymethacrylic acids crosslinked or not crosslinked polyacrylic acids crosslinked or not crosslinked polysulphonic acids and or carboxyl salts and or phosphonic salts and or iminodiacetic salts and or alkylphosphonic salts and or aikylsulphonic salts and or alkylarylsulphonic salts snd or aikylphosphonic salts membranes and filaments onto which acidic functional groups have been grafted halogenated and or partly halogenated polymers and or copolymers containing acidic functional groups. The acidic polymers or copolymers have a gel, or macroreticular or macro porous or isoporous structure. Let us consider e.g. the polystyrenesulphonic resin PS the molecular weight of this resin is higher than 100 DALTON, preferably higher than 1,000 and still more preferably, higher than 11000,000 DALTON. In the case Df polystyrenesulphonic copolymer, the crosslinking degree preferred is lower than 906 w w, preferably lower than 105S, and still more preferably lower than 6 . PS Polymer has preferably, but not limitedly, a gel structure with high porosity. In the case of polystyrenesulphonic polymer, the physical dimension of the copolymer used to prepareSAM salt is comprised within the range of from 10 mm to 0.001it, preferably of from 1,000 to 11t, and still more preferably, of from 500 to 20cm. The characteristic moisture content of the polymer is higher than 0,5 of its weight preferably higher than 50 of its weight moisture holding capacity . The exchange capacity is larger than 0.1 equivalents per kilo of dry copolymer. In general, according to the present invention, aSAM resin salt is prepared by reacting the resin contain ing the acidic functional groups in the selected ionic form, with a SAM containing solution. An object of the present invention is also having prepared a SAM resin salt of pharmaceutical grade by directly reacting an ion exchange resin with the SAM contained within the lysate of microorganism cells. The resins which are preferentially but not limit edly used to this purpose are for instance pertaining to the following types Amberlite ER 151 BR 152 IR 120 Anberlite IRP 69 Trade name Roehm and Haas , finely subdivided Cenalit 5000, Bayer Duolite C 204 F, Diaprosim Duolite C 20 Duolite C 25 Duolite C 26 Duolite C 264 Duolite ES 467 Wofatit XPS, Wofatit Wofetit KPS AS Dowex HOR W, Dow Dowex 50 W Kastel C 300, Montedison Imacti C 12, AKZO Zerolit 225, Zeokarb Pielite CF, Resindion In the following Examples, the lysate outcomes from cells of Saccaromyces cerevisiae bread yeast . Other microoranisms with similar characteristics have been used with similar results. The process has shown to be extremely simple and economically advantageous, in comparison to the techniques of the prior art. The recovery of SAM from the lysate is between 90 and 100 . The purity of SAM contained in the resin salt has been between 90 and 100 . The reaction time has been comprised within the range of from O, n to 60 . The reaction temperature is comprised between the freez ing point of SAM containing solution to be reacted, and the decomposition temperature of SAM PS, prefer ably the room temperature. The preferred reaction pH is comprised.between 0 and 6 with the salified resin in the Na form. Some non limitative Examples are reported, of preparation of a salt according to the invention. Example 1 A SAM polystyrenesulphonate salt is prepared by dis solving a SAM salt, equivalent to 1 g of SAlE in 50 ml of water. The pH is adjusted, if necessary, at a value between 1.5 and 3. The reaction takes place at room tem perature. The mixture is thoroughly stirred, then, under stirring, 2.0 g are added of sodium polystyrenesulphonate,USP grade, commercially available calculated on dry weight basis . Stirring is continued for about 15 , then the reaction mixture is filtered, recovering the solid portion, which is washed with 300 ml of distilled water, and. then dried overnight in the vacuum, in an oven at 500C. 3.00 g of SAM resin salt are obtained. The compound contains 33 by weight of SAM, at a purity of 98 99ffi. A sample of such product has been used for SAM re lease tests, both in simulated gastric and simulated enteric juice, with the following results. Percentage released at pH 2 practically nil in 1 hr. Percentage released at pH 6 practically nil in 1 hr. Percentage released at pH 7 about 105 in 1 hr. Percentage released at pH 8 higher than 95 within 15 minutes. Example 2 51000 g of yeast cells of the Saccaromyces cerevisiae type, previously enriched in SAM according to theSchlenk method J. Biol. Chem. 229 1,037 1957 U.S.Pat. 3X962X034, Jun 8th 1976 , are suspended in 30 litres of deionized water, and subsequently lysed. The end pH is adjusted at a value of about 2. The lysate is clarified. Found SAM is 65 g. To a share of clarified liquid, equivalent to 50 g of SAM ,100 g are added, under stirring, of sodium poly styrenesulphonate Amberlite IRP 69 calculated on dry basis . Contact time 15 . Sulphonated polystyrene cap tures selectively SAM . The whole reaction mass is filtered, recovering, this time, the solid portion. The recovered solid portion is washed with 6 litres of distilled water. The washed solid is dried at 500C, in the vacuum, overnight.145.5 g are obtained of SAM resin salt containing 30 รณ of SAM at a purity of 95.5. The extraction yield has been of 95. Example 3 1 litre of a solution of SAM, purified by means of ion exchange U.S. Pat. 31962t034, June 8th 1976 Chem.Abstr. 1982, sol. 96, 118506 E containing 4,5 g of SAM is started being stirred, controlling pH between 1.5 and 3 and then 9 g are added of sodium polystyrenesulphonate calculated on dry basis . The mixture is stirred for 15 , then it is filter ed, and the solid portion is collected. The recovered solid is dried overnight at 5000 in the vacuum. 12,7 g of product are obtained, containing 33 of SAM , at a purity level of 98,39 . Example 4 1 litre of solution as described in Example 3 has been concentrated down to 500 ml. The value of pH has been controlled to be between 1.5 and 3.0. 9 g of sodium polystyrenesulphonate calculated on dry basis have been added, and the mixture has been stirred for a time of 45 . The reaction mixture has been filtered, recovering the solid portion, the recovered solid has been dried overnight at 500C in the vacuum. 13 g have been obtained of product at a purity lev el of 98.7 .Exemplifying characteristics of a SAM polystyrene sulphonate salt SAM PS SAM in SAM PS 33910 determined at U.V. Spectropho tometer at 260 nm Appearance powder of white inclining to cream colour solubility insoluble in water, acids and organ ic solvents SAM release from SAM PS in simulated gastric solu tions, SAM is not virtually released. Biologically significant quantities of SAM can be released starting from pH values around neutra lity, till to a practically complete release at basic pH values.The release of SAM, which is in a soluble and absorbable form, can be controlled within the suit able pH range by means of the addition of proper sub stances Moisture 2 8 Melting point decomposes above 10000 with out melting. Ashes about 15 . Hygroscopicity practically nil. Purity of released SAM 98 . Heavy metal content following USP method approved. Shelf life at room temperature the product is storable for long time periods. Toxicity non toxic. Stability at 500C see following Table.Temperature Moisture con Exposure time Residual SAM OC tent of SAM7 days relatively to PS powder original con w w tent 50 1.5 5 96.5 50 1.5 8 94 50 1.5 12 92 50 1.5 15 91 50 3.5 5 90.4 50 3.5 8 94 50 3.5 12 86 50 3.5 15 85.3Table Stability tests of SAM PS salt A comparison among known and available commercial products and the product according to the invention, a bove exemplified, can be seen from the following ta bleO PRODUCT SAM.C1 SA,SO, SAM.SO SO4 SAM.PS TS Appearance White White White Sand col powder powder powder oured pow derSolubility in water Yes Yes Yes NoSolubility in acids Yes Yes Yes NoGastroresistance Nil Nil Nil Very good Hygroscopicity High High High NilFlow characteristics Nil Nil Nil Flowing powderShelf life at room temperature, with 4 of moisture Nil Nil Nil Storable compoundStabilityResidual of SAM af ter storage of the salt with 1 moisture for 2 weeks at 450C 32 48 61 96,4Pharmaceutical uses Unknown Unknown Parental All uses only possible TS Tosylate When an insoluble salt according to the invention is treated with a salt solution, such as e.g. physiological ly compatible buffer solutions, at a plI equal to and or higher than 7, and with an adequate molarity, it releases SAM cation, salified with the anion or the anions used, such cation therefore passing into the solution. Some examples are now reported, for illustrative and not limitative purposes, of preparation of pharmaceutic al compositions according to the invention. Example 5Preparation of tablets of SAM polystyrene sulphonate SAM PS A tablet of 2OOmgof SAM contains SAM resin salt equivalent to 200 mg of SAM 606 mg Excipients for tablet forming as much as ne cessary SAM resin salt, salts and the excipients for tab let forming are mixed together. The mixture is directly compressed in the dry state. Examples 5A 5B Preparation of tablets of SAM polystyrene sulphonate SAM PS 5A A tablet of 200 mg of SAM contains SAM resin salt 606 mg Excipients for tablet forming as much as ne cessary Gastroresistant protection as much as ne cessary SAM. PS and excipients are mixed. The mixture is directly compressed in the dry state. The tablet obtained is coated with gastroresistant resin to the purpose of achieving its integral transportation to the enteric environment. If desired, the coated tablet can be sugar coated to a pill.5B Same as Example 5A SAM resin salt 606 mg Excipients as much as necessary Release controlling salts e.g., K2C03, Ca HCO , K2HP04, K3P04, and so on as much as necessary Example 6Preparation of suppositories with SAM polystyrene sul phonate SAM PS SAM PS 606 mg Mass for suppositories as much as ne cessary The mass for suppositories is molten, and SAM PS is suspended inside it. The mass is homogenized and is poured inside the suitable mould, controlling the previously selected weight, and leaving it to cool after having sealed its envelope. Example 6APreparation of suppositories with SAM polystyrene sulphonate SAM PS A suppository of 200 mg of SAM contains SAM resin salt equivalent to 200 mg of SAM as much as ne cessary Mass for suppositories, free from water ditto SA release control salts ditto The mass for suppositories is molten, and within it the salts and SAM PS are suspended. The mixture is homogenized and poured inside the suitable mould, control ling the previously selected weight and leaving it to cool after having sealed the envelope. Example 7Extemporary suspension syrup of SAM PS, single dose A vial or bag of 0.250 g of SAM contains SAM PS equivalent to 0.250 g of SAM 757 mg Excipients as much as ne cessary Thoroughly mix SAM resin salt and the excipients together, and dose the preselected quantity of mixture inside a single dose vial or inside a container with a shearer, or inside a bag. Example 8Preparation of hard capsules of SAM PS A capsule of 100 mg of SAM contains SAh l, PS equivalent to 100 mg of SAM 303 mg Excipients Binders lubricants as much as ne cessary SAM PS is thoroughly mixed with the binders and the lubricants, and is then dosed inside a gelatine capsule. Example 9Preparation of injectable solutions of SAM PS A vial of 500 mg of SAM contains SAM PS equivalent to 500 mg of SAM 1X515 mg A sterilized solvent vial for the said vial contains an organic or inorganic salt of Na, K, Ca, capable of giving a solution with a pH value suitable for causing SAM to be released from the resin salt as much as ne cessary Water, injection grade ditto SAM resin salt, after having been sterilized, is dosed inside vials of the penicillin type, and sealed by the.serile technique. The solution to be injected is formed by introducing, by means of a syringe with a needle of size NO 1, the suitable solvent inside the vial, at the time of use. The suspension is sucked inside the syringe. The needle is replaced with a system needle 0.22,u filter.The solution of SAM can be injected, whilst the resin possibly present remains upstream of the filter. Summarizing, the invention allows a salt to be ob tained, whose main characteristics are stability capability of being compacted and compressed absence of hygroscopicity insolubility in water and in gastric juice easy release of SAM ion in basic environment and in enteric juice possibility of obtaining in vitro and in .vivo, by means of interchange reactions, SAM ions salified with desired anionic radicals phosphates, lac tates, glycerophosphates , by mixing measured and desir ed quantities of Na, X, Ca salts, and so on, containing precisely phosphates, lactates, glycerophosphates, and so on, as the anionic moiety, with the SAM resin salt. Further advantages of the invention are the stabi lity and easiness of handling of the salt in the common ly used pharmaceutical compositions, as well as the eco nomy of the preparation processes of such salts, and in addition, the possibility of preparing gastroresistant, that is, delayed, compositions. The possibility of releasing the active moiety al lows this drug to be used also in cutaneous and transdermal compositions. The insoluble salt can be administered under various pharmaceutical forms, such as for instance hard or soft capsules tablets with quick, slow, or controlled release sugar coated pills, pills, suspensions, suppositories, vaginal tablets, powders. The most suitable therapeutical use appears to be in the treatment of arthritis, periarthritis, and at cerebral level in depression syndromes. A particular characteristic of pharmaceutical technique which makes this novel salt different to the other SAK salts presently commercially available, is that it can be used both for solid and liquid pharmaceutical forms. The most suitable use of the compositions according to the invention is in the human and veterinary pharmaceutical field the invention however may be usefully employed also in the alimentary, agrarian, biological or generally chemical fields, in the zootechnic field, in the cosmetic field, and in other fields.